Innosuisse is looking for experts

Monday, May 26, 2025 @ 12:00 am

The Innosuisse Innovation Council is currently looking for qualified experts to assist in reviewing funding applications, supporting innovation projects and implementing various innovation promotion activities. The task of these experts is to evaluate and make recommendations for the approval or rejection of funding applications for innovation projects.

The experts act on behalf of Innosuisse within the framework of a mandate, in accordance with the applicable legal and regulatory provisions. Their remuneration is defined by the Innosuisse Remuneration Ordinance, with flat fees per case. In principle, Their actual workload is usually closer to 5% to 15%, which can be managed flexibly. This percentage depends both on the number of applications received by Innosuisse and on the availability of the individual experts, who may also accept or reject the work offered to them in order to optimise their time management.

Find more and apply here by June 9.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

GlycoEra: USD 130 million for the treatment of autoimmune diseases

Financing led by Novo Holdings with significant support from world-class group of existing and new investors. Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated precision immunology pipeline.
May 27, 2025

ten23 health: Advisory board in collaboration with St. Gallen Symposium

May 27, 2025

ORYL introduces laser-based platform for measuring solubility and molecule aggregation

ORYL Photonics introduces the ORYL F1, a novel automated laser-based platform for the measurement of solubility and aggregation of drug molecules in the Life Science industry. This is a significant achievement for the fast-growing Swiss company and for the solubility and aggregation community. The laboratory instrument enables researchers to make faster decisions and gain a deeper understanding of
May 22, 2025

Cosmo valuation report: GI Genius, Winlevi, and Breezula to drive future growth

May 13, 2025

Pharvaris: Q1 2025 financial results and business update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines TQT study waivers received from FDA for both deucrictibant extended-release f
May 13, 2025